Initiator Pharma Company Description

Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system.

Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain.

Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark.

Initiator Pharma A/S

Country	Denmark
Founded	2016
Industry	Biotechnology
Sector	Healthcare
Employees	2
CEO	Claus Olesen

Contact Details

Address: Ole Maaloes vej 3 Copenhagen, 2200 Denmark
Phone	45 61 26 00 35
Website	initiatorpharma.com

Stock Details

Ticker Symbol	INIT
Exchange	Nasdaq Stockholm
Fiscal Year	January - December
Reporting Currency	DKK
ISIN Number	DK0060775872
SIC Code	2836

Key Executives

Name	Position
Dr. Claus Elsborg Olesen	Co-Founder, Chief Executive Officer and Director
Dr. Dan Peters Ph.D.	Co-Founder and Chief Technology Officer
Prof. Ulf Simonsen Ph.D.	Co-Founder, CMO and CSO
Dr. Mikael Thomsen M.Sc., Ph.D.	Co-Founder and Chief Development Officer
Dr. Torgeir Vaage Ph.D.	Chief Financial Officer
Dr. Allan Wehnert	Senior Vice President of Clinical and Research & Development Strategy and Portfolio Management
Susanne Thomsen	Head of Clin Ops
Rene Egebro M.Sc.	Head of CMC